Nurix therapeutics announces presentations at the 5th annual targeted protein degradation (tpd) summit

San francisco, oct. 19, 2022 (globe newswire) -- nurix therapeutics, inc. (nasdaq: nrix), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced that it will make several presentations, including a keynote plenary presentation by arthur t. sands, m.d., ph.d., nurix's president and chief executive officer, at the 5th annual tpd summit which is being held october 25‒28, 2022, in boston, ma.
NRIX Ratings Summary
NRIX Quant Ranking